Global Erlotinib Hydrochloride Market Data Survey Report 2025 [Report Updated: 07092017] Prices from USD $1500
Summary
Erlotinib Hydrochloride is an anticancer drug from protein kinase inhibitors pharmacological group. This medication is used for the treatment of nonsmall cell lung cancer NSCLC, locally advanced, unresectable or metastatic pancreatic cancer, and several other types of cancer. It is usually given after other cancer medicines have been tried without success. Erlotinib acts on the epidermal growth factor receptor EGFR, and it works by interfering with the growth of cancer cells and slows their spread in the body
The global Erlotinib Hydrochloride market will reach xxx Million USD in 2017 with CAGR xx% 20182025. The main contents of the report including:
Global market size and forecast
Regional market size, production data and export import
Key manufacturers manufacturing sites, capacity and production, product specifications etc.
Average market price by SUK
Major applications
Key manufacturers are included based on manufacturing sites, capacity and production, product specifications etc.:
Roche
Cipla
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Raichem Lifesciences
United Biotech
CJ Corporation
Vivimed Labs
Boryung Pharmaceutical
Taj Pharmaceuticals
Pharmascience
Natco Pharma
Intas Pharmaceuticals
RPG Life Sciences
Pharmascience
Schwarz Pharma
Dr. Reddy's Laboratories
Glenmark Pharmaceuticals
Chugai Pharmaceutical
DKSH
Firma Chun Cheong
Kremers Urban Pharmaceuticals
Ortat
Zuellig Pharma
Major applications as follows:
Nonsmall Cell Lung Cancer
Pancreatic Cancer
Regional market size, production data and export import:
AsiaPacific
North America
Europe
South America
Middle East Africa
Original Article: Global Erlotinib Hydrochloride Market Data Survey Report 2025 [Report Updated: 07092017] Prices from USD $1500
